| 1. |
Schou M. Forty years of lithium treatment. Arch Gen
Psychiatry 1997;54:9-13. |
| 2. |
Alvarez E, Pérez-Solá V, Pérez-Blanco J,
Queraltó JM, Torrubia R, Noguera R. Predicting outcome of lithium
added to antidepressants in resistant depression. J Affect Disord
1997;42:179-86. |
| 3. |
Joffe RT, Calabrese R. Anticonvulsants in mood disorders. New York:
Marcel Dekker Inc.; 1994. |
| 4. |
Vieta E, Gastó C, Colom F, Martínez A, Otero A,
Vallejo J. Treatment of refractory rapid cycling bipolar disorder with
risperidone. J Clin Psychopharmacol. En prensa 1998. |
| 5. |
Saiz-Ruiz J, Moral L. Tratamiento de los estados mixtos y
cicladores rápidos. En: Vieta E, Gastó C, editores.
Trastornos bipolares. Barcelona: Springer-Verlag; 1997. p. 361-87. |
| 6. |
Perucca E. Pharmacokinetic profile of topiramate in comparison with
other new antiepileptic drugs. Epilepsia 1996;37(Supl 2):8-13. |
| 7. |
Ferrier IN. Epileptic agents in bipolar disorder. Eur
Neuropsychopharmacol 1996;6(Supl 4):30. |
| 8. |
Nolen WA. Treatment options in refractory bipolar disorder,
methodological problems and clinical opportunities. Eur
Neuropsychopharmacol 1996;6(Supl 4):31. |
| 9. |
Kupferberg HJ. Other experimental antiepileptic drugs. En: Resor
SR, Kutt H, editors. Neurological disease and therapy. Nueva York:
Michael Dekker Inc; 1992. p. 661-8. |
| 10. |
Taylor CP. Mechanism of action of new anti-epileptic drugs. En:
Chadwick, editor. New trends in epilepsy management: The role of
gabapentin. Londres: Royal Society of Medicine Services Limited; 1993.
p. 13-40. |
| 11. |
Dubovsky SL, Buzan RD. Novel alternatives and supplements to
lithium and anticonvulsants for bipolar affective disorder. J Clin
Psychiatry 1997;58:224-42. |
| 12. |
Suman-Chauhan N, Webdale L, Hill DR. Characterisation of [3H]
gabapentin binding to a nobel site in the rat brain: homogenate binding
studies. Eur J Pharmacol Mol Pharmacol 1993;244:293-301. |
| 13. |
Anhut H, Ashman P, Feuerstein TJ. Gabapentin (Neurontin) as add-on
therapy in patients with partial seizures: a double-blind, placebo
controlled study. Epilepsia 1994;35:795-801. |
| 14. |
Dichter MA, Brodie MJ. New antiepileptic drugs. New Engl J Med
1996;334:1583-90. |
| 15. |
Vieta E, Gastó C. Avances en el tratamiento de los
trastornos bipolares: posibilidades terapéuticas de la
gabapentina. Psiquiatr Biol 1997;4:158-61. |
| 16. |
Vieta E, Gastó C. Perspectivas en el diagnóstico y
tratamiento de los trastornos bipolares. En: Vieta E, Gastó C,
edotores. Trastornos bipolares. Barcelona: Springer-Verlag; 1997. p.
445-53. |
| 17. |
Ryback R, Ryback L. Gabapentin for behavioral dyscontrol. Am J
Psychiatry 1995;152:1399. |
| 18. |
Dodrill CB, Wilensky AJ, Ojemann LM, Temkin NR, Shellenberger.
Neuropsychological, mood and psychosocial effects of gabapentin.
Epilepsia 1992;33:117. |
| 19. |
Walden J, Hesslinger B. Bedutung alter und neuer antiepileptika in
der behandlung psychischer erkrankungen. Fortschr Neurol Psychiat
1995;63:320-35. |
| 20. |
Short C, Cooke L. Hypomania induced by gabapentin. Br J Psychiatry
1995;166:679-80. |
| 21. |
Hauck A, Bhaumik S. Hypomania induced by gabapentin. Br J
Psychiatry 1995;167:549. |
| 22. |
Stanton SP, Keck Jr PE, McElroy SL. Treatment of acute mania with
gabapentin. Am J Psychiatry 1997;154:287. |
| 23. |
Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania:
reliability, validity and sensitivity. Br J Psychiatry 1978;113:429-35. |
| 24. |
McElroy SL, Soutullo CA, Keck PE Jr, Kmetz GF. A pilot trial of
adjunctive gabapentin in the treatment of bipolar disorder. Ann Clin
Psychiatry 1997;9:99-103. |
| 25. |
Young LT, Robb JC, Patelis-Siotis I, MacDonald C, Joffe RT. Acute
treatment of bipolar depression with gabapentin. Biol Psychiatry
1997;42:851-3. |
| 26. |
Schaffer CB, Schaffer LC. Gabapentin in the treatment of bipolar
disorder. Am J Psychiatry 1997; 54:291-2. |
| 27. |
Vieta E, Colom F, Martínez-Arán A, Gastó C.
Trastorno bipolar refractario: un caso de respuesta favorable a la
gabapentina. An Psiquiatr. En prensa. |
| 28. |
Weisler R, Risner ME, Ascher J, Houser T. Use of lamotrigine in the
treatment of bipolar disorder. American Psychiatric Association Meeting
Abstracts, 1994: 611. |
| 29. |
Ketter TA, Frye MA, Cora-Locatelli G, Kimbrell TA, Post RM.
Pharmacology and pharmacokinetics of new anticonvulsants. American
Psychiatric Association Meeting Syllabus, 1997: 84-85. |
| 30. |
Calabrese JR, Fatemi SH, Woyshville MJ. Antidepressant effects of
lamotrigine in rapid cycling bipolar disorder. Am J Psychiatry
1996;153:1236. |
| 31. |
Fatemi SH, Rapport DJ, Calabrese JR, Thuras P. Lamotrigine in
rapid-cycling bipolar disorder. J Clin Psychiatry 1997;58:522-7. |
| 32. |
Calabrese J, Bowden C, McElroy J, Cookson J, Anderson J. Lamictal
monotherapy in the treatment of bipolar disorder. Eur
Neuropsychopharmacol 1997;7(Supl 2):177. |
| 33. |
Frye MA, Ketter TA, Kimbrell TA, Cora-Locatelli G, Dunn RT, Post
RM. Gabapentin and lamotrigine monotherapy in mood disorder. American
Psychiatric Association Meeting Syllabus, 1997: 85. |
| 34. |
Calabrese J, Bowden C, McElroy J, Cookson J, Anderson J, Rhodes LJ,
et al. Lamotrigine in bipolar disorder: preliminary data. American
Psychiatric Association Meeting Syllabus, 1997: 85. |
| 35. |
Sussman N. Gabapentin and lamotrigine: Alternative agents for the
treatment of bipolar disorder. Primary Psychiatry 1997:25-42. |
| 36. |
Freeman MP, Stoll AL. Mood stabilizer combinations: a review of
safety and efficacy. Am J Psychiatry 1998;155:12-21. |
| 37. |
Post RM, Ketter TA, Denicoff K, Pazzaglia PJ, Leverich GS,
Marangell LB, et al. The place of anticonvulsant therapy in bipolar
illness. Psychopharmacology 1996;128:115-29. |
| 38. |
Sander JW, Hart YM, Trimble MR, Shorvon SD. Vigabatrin and
psychosis. J Neurol Neurosurg Psychiatry 1991;54:435-9. |
| 39. |
Kanba S, Yagi G, Kamijima K et al. The first open study of
zonisamide, a novel anticonvulsant, shows efficacy in mania. Prog
Neuropsychopharmacol Biol Psychiatry 1994;18:707-15. |
| 40. |
The Lancet. Oxcarbazepine. Lancet 1989;2:196-8. |
| 41. |
Emrich HM, Dose M, Von Zersen D. The use of sodium valproate,
carbamazepine and oxcarbazepine in patients with affective disorders. J
Affect Disord 1985;8:1-16. |
| 42. |
Cabrera JF, Muhlbauer HD, Schley J, Stoll KD, Muller-Oerlinghausen
B. Long-term randomized clinical trial on oxcarbazepine vs. lithium in
bipolar and schizoaffective disorders: preliminary results.
Pharmacopsychiatry 1986;19:282-3. |
| 43. |
Kouzavkova M,. Mosolov S, Kostiukova E, Singin A.
Clinico-pharmacokinetic prognosis of prophylactic efficacy of
carbamazepine, oxcarbazepine and sodium valproate in affective and
schizoaffective disorders. Eur Neuropsychopharmacol 1996;6(Supl 4):90. |
| 44. |
Canger R, Guidolin R, Di Fazio M, Canevini MP, Sgrò V,
Satarelli A, Piazzini A. Topiramate in the treatment of partial
refractory epilepsy: an open-label study with long-term follow-up.
Second European Congress of Epileptology; 1996; La Haya. |
| 45. |
Shorvon SD. Safety of topiramate: adverse events and relationship
to dosing. Epilepsia 1996;37(supl 2):18-22. |
| 46. |
McInnis MG, McMahon FJ, Chase GA, Simpson SG, Ross CA, De Paulo Jr
R. Anticipation in bipolar affective disorder. Am J Hum Genet
1993;53:385-90. |
| 47. |
Wehr TA, Sack DA, Rosenthal NE, Cowdry RW: Rapid cycling affective
disorder: Contributing factors and treatment responses in 51 patients.
Am J Psychiatry 1988; 45:179-84. |
| 48. |
Goodwin FK, Jamison KR. Manic-Depressive Illness. New York: Oxford
University Press; 1990. |
| 49. |
Post RM, Leverich GS, Altshuler L, Mikalauskas K.
Lithium-discontinuation-induced refractoriness: preliminary
observations. Am J Psychiatry 1992;149:1727-9. |
| 50. |
Maj M, Pirozzi R, Magliano L. Nonresponse to reinstituted lithium
prophylaxis in previously responsive bipolar patients: Prevalence and
predictors. Am J Psychiatry 1995;152:1810-1. |
| 51. |
Andreasen NC. Changing concepts of schizophrenia and the
ahistorical falacy. Am J Psychiatry 1994;151:1405-7. |
| 52. |
Gastó C, Arrufat F. Tratamiento psicofarmacológico de
la manía. En: Vieta E, Gastó C, editores. Trastornos
bipolares. Barcelona: Springer-Verlag; 1997. p. 337-48. |
| 53. |
Pérez-Solá V, Pérez-Blanco J. Etiopatogenia:
fisiopatología. En: Vieta E, Gastó C, editores. Trastornos
bipolares. Barcelona: Springer-Verlag; 1997. p. 73-116. |
| 54. |
Vieta E. Trastornos bipolares. En: Vallejo J, Gastó C.
Trastornos afectivos: ansiedad y depresión. 2a. edición.
Barcelona: Salvat; en prensa. |
| 55. |
Leiderman D, Koto E, Lamoreaux L. Gabapentin therapy and quality of
life: side effects in placebo-controlled studies. Epilepsia 1993;34(Supl
6):45. |
| 56. |
Bennett J, Goldman WT, Suppes T. Gabapentin for treatment of
bipolar and schizoaffective disorders. J Clin Psychopharmacol
1997;17:141-2. |
| 57. |
Marcotte DB, Fogleman L, Wolfe N, Nemire R. Gabapentin: An
effective therapy for patients with bipolar affective disorder. New
Research Program and Abstracts of the 150th Annual Meeting of the
American Psychiatric Association; 1997. p. 138. |